Κατεύθυνση Μοριακή Ιατρική Βιοπαθολογία
Library of the School of Health Sciences

2022-06-15

2022

Petropoulou Dimitra

Σπυρίδων Πουρνάρας, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Σοφία Βουρλή, Ph.D., Βιολόγος, Ακαδημαϊκή υπότροφος, ΕΚΠΑ
Βασιλική Πιτυρίγκα, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Μελέτη νεότερου αναστολέα β-λακταμασών σε ανθεκτικά στις καρβαπενέμες στελέχη Acinetobacter baumannii

Greek

Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece

BACKGROUND: Acinetobacter baumannii is a leading cause of healthcare-associated
infections worldwide, due to both its persistence in the hospital setting and its ability to
acquire high levels of antibiotic resistance. Carbapenem-resistant A. baumannii isolates
(CRAb) limit the spectrum of action of current antimicrobial approaches. Thus, it is
imperative to look for alternatives or adjuncts to traditional antibiotics therapies.
Durlobactam is a novel broad-spectrum inhibitor of serine-type beta-lactamases that
restores sulbactam (SUL) activity against A. baumannii, which possess multiple βlactamases. The sulbactam-durlobactam (SD) combination is currently in Phase 3
testing in the global ATTACK trial.
OBJECTIVES: The aims of this study are to evaluate the activity of sulbactamdurlobactam versus comparators against a nationwide collection of carbapenemresistant A. baumannii (CRAb) isolates.
METHODS: 190 A. baumannii clinical isolates were collected from numerous body
sites across Greece during 2015. The in vitro activities of sulbactam-durlobactam and
comparators were determined by broth microdilution.
RESULTS: The addition of durlobactam restored the activity of sulbactam against
most of the strains tested. The MIC90 of sulbactam-durlobactam was 4 µg/ml, compared
with 64 µg/ml for sulbactam alone. The resistance rates for sulbactam and colistin were
100% and 32,4%, respectively. 87.5% of the isolates had sulbactam-durlobactam MICs
of ≤ 4/4 µg/ml.
CONCLUSIONS: This study demonstrated the potential utility of sulbactamdurlobactam for the treatment of infections caused by A. baumannii. If clinical efficacy
is confirmed, sulbactam-durlobactam may be an important therapeutic option for
infections due to multidrug resistant A. baumannii

Health Sciences

Β-lactamase inhibitor, CRAB, Acinetobacter baumannii

No

0

Yes

175

98

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/3218289